Janssen Immunology has expanded our pipeline and portfolio beyond anti-cytokine antibody treatments, to include the development of novel therapeutics to treat a subset of immune-mediated diseases called autoantibody diseases which are caused by pathogenic antibodies made by one’s own body that attack critical organs. These novel therapeutics also have potential to treat rare maternal-fetal conditions that may occur during pregnancy when a woman develops antibodies that can cause her immune system to attack her unborn child’s blood cells.

Our research has the potential to help the estimated 240 million people worldwide who suffer from autoantibody diseases, many of which have no safe, effective treatments. As a part of our mission to redefine treatments for immune diseases, Janssen Immunology aims to revolutionize care for patients with a novel therapy that reduces pathogenic antibodies while safely maintaining immune function.

Learn more about autoantibodies on JNJ.com

REFERENCES

Eggert M, Zettl, et al. Autoantibodies in autoimmune diseases. Curr Pharm Des. 2010 May;16(14):1634-43. DOI: 10.2174/138161210791164144. PMID: 20196735.
Ludwig Ralf J., et al. Mechanisms of Autoantibody-Induced Pathology. Frontiers in Immunology. 2017. 603. DOI: 10.3389/fimmu.2017.00603. ISSN=1664-3224.